At SITC 2026, 10 of 15 patients with advanced melanoma responded to investigational amsokigene autoleucel at the recommended phase 2 dose, with 5 still in response 12 months after infusion.
News|Videos|December 14, 2020
Common Prior Treatments of Participants in the MOST Study
Rami Komrokji, MD, discusses common prior treatments of low-risk and intermediate-1 risk patients in the MOST study.
Advertisement
In an interview with Pharmacy Times, Rami Komrokji, MD, clinical director of malignant hematology and department lead clinical investigator at the H. Lee Moffitt Cancer Center and Research Institute, spoke about common prior treatments among low-risk and intermediate-1 risk patients in the MOST study. Komrokji presented at the 62nd American Society of Hematology Annual Meeting and Exposition on ‘To Treat or Not to Treat? Understanding Treatment Patterns in Patients with Lower-Risk Myelofibrosis at the Time of Enrollment in the MOST Study.’
Advertisement
Related to this article
Matthew Porteus, MD, PhD, highlighted preclinical advances in automated stem cell gene editing that could improve manufacturing scalability while supporting the development of next-generation genetic medicines.
Experts highlighted recent gene therapy approvals for inherited immune disorders while addressing ongoing challenges in manufacturing, long-term safety, and patient access.
At the 2026 ASTCT Gene Therapy Summit, experts highlighted how chronic pain, psychological challenges, and neurologic complications may persist despite successful treatment.
SCOUT-HCM data show LVOT gradient reductions persisted, patients switching from placebo responded similarly, and no patient had LVEF below 50%.
On NET Cancer Day, a return visit for an over-the-counter antidiarrheal illustrates how pharmacists can identify a symptom pattern and help patients seek evaluation.
A community oncology pharmacist explains how seeing patients across the course of their diagnosis builds trust and why accessibility remains the field’s biggest challenge despite advances in AI.
Adding the IL-15 agonist to frontline BCG improved responses in carcinoma in situ without new safety signals; full data are expected at an upcoming congress.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Asundexian Receives FDA Approval, Becomes First FXIa Inhibitor for Secondary Stroke Risk Reduction
2
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
3
mRNA vs Protein-Based COVID-19 Vaccines: What Pharmacists Can Tell Patients
4
Lilly–Hims & Hers GLP-1 Deal Tests Whether Convenience Can Deliver Continuity of Care
5